Physician profile
Alexander Phan
NPI 1245816784
$2,195.73
in general payments reported to CMS, 2019-2025
13 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $151 · 2024: $815 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,101 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,100.73 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $298.56 | 2025 | Alphavac |
| Stryker Corporation | $284.91 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Flowtriever |
| Janssen Pharmaceuticals, INC | $282.27 | 2024 | Xarelto |
| Gilead Sciences, INC. | $243.63 | 2023-2024 | Epclusa |
| Madrigal Pharmaceuticals | $242.66 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $226.34 | 2024 | Lokelma, Farxiga |
| Pulmonx Corporation | $158.44 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Genzyme Corporation | $124.99 | 2025 | |
| Glaxosmithkline, LLC. | $121.82 | 2025 | Nucala |
| Astellas Pharma US INC | $95.00 | 2025 | |
| Pinnacle Biologics, INC | $61.41 | 2025 | Photofrin |
| Amgen INC. | $29.37 | 2023 | Otezla |
| Puma Biotechnology, INC. | $26.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.